...A. Eplontersen for TTR amyloidosis, Olezarsen for diseases related to severely elevated triglycerides and donidalorsen, our prophylactic treatment for HAE, all going very well, as is our really broad late-stage Phase III pipeline. B. Today, we have 8 drugs, including those 3 for 10 disease indications, both rare and broad indications, and they're all firing on all cylinders, going well on track for their scheduled readouts. C. We're pleased with the performance of our lead commercial product with Biogen, SPINRAZA. D. And we're really pleased with the approval of QALSODY earlier this year, a drug that was discovered and conceived by Ionis and then now launched by our partner, Biogen, for a genetic form of ALS. E. QALSODY is the first drug ever to target a genetic cause of ALS and probably the first drug that will actually have a disease-modifying impact on patients with ALS. F. And it also represents our second drug from our vast neurodegenerative neurological disease pipeline today, which...
